Physician profile
Guy E Brannon
NPI 1164481875
$6,443.05
in general payments reported to CMS, 2019-2025
27 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.48 · 2020: $29.02 · 2021: $440 · 2022: $897 · 2023: $1,668 · 2024: $1,597 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,003 · Education: $6.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,003.47 |
| Education | $6.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $974.80 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $888.36 | 2021-2025 | Vraylar |
| Alkermes, INC. | $823.05 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $526.29 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $516.56 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $472.85 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $419.97 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $416.83 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $292.34 | 2021-2024 | Trintellix |
| Indivior INC. | $191.44 | 2023-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $174.02 | 2024-2025 | Cobenfy |
| Braeburn INC. | $149.04 | 2024-2025 | Brixadi |
| Livanova USA, INC. | $118.31 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Axsome Therapeutics, INC. | $105.70 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $102.67 | 2021-2024 | Fanapt, Hetlioz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $89.41 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $61.50 | 2021 | |
| Bioxcel Therapeutics, INC. | $39.71 | 2024 | Igalmi |
| Collegium Pharmaceutical, INC. | $31.54 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $23.50 | 2023 | Qelbree |
| Almatica Pharma LLC | $14.00 | 2024 | Loreev Xr |
| Allergan, INC. | $11.16 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Brannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.